EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark Psycheceuticals was filed as Word mark on 11/10/2021 at the European Union Intellectual Property Office.
It was registered as a trademark on 03/08/2022.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 018597974 |
| Application date | November 10, 2021 |
| Publication date | November 29, 2021 |
| Entry date | March 8, 2022 |
| Expiration date | November 10, 2031 |
Trademark owner
1 ADELAIDE STREET EAST Suite 801
M5C 2V9 TORONTO
CA
M5C 2V9 TORONTO
CA
Trademark representatives
Paulus Potterstraat 20 HS
1071 DA Amsterdam
NL
goods and services
5
Pharmaceuticals for treating organic mental disorders; pharmaceuticals for treating symptomatic mental disorders; pharmaceuticals for treating mental and behavioural disorders; pharmaceuticals for treating endocrine; Pharmaceuticals for treating nutritional and metabolic diseases; pharmaceuticals for treating degenerative cerebral disease; pharmaceuticals for treating dementia; pharmaceuticals for treating dementias; pharmaceuticals for treating organic amnesic syndrome; pharmaceuticals for treating mental and behavioural disorders due to use of alcohol; pharmaceuticals for treating hallucinosis; Pharmaceuticals for treating mental disorders; Pharmaceuticals for treating schizophrenic disorder Pharmaceuticals for treating depression; Pharmaceuticals for treating mood disorders; pharmaceuticals for treating mental and behavioural disorders due to psychoactive substance use; pharmaceuticals for treating schizophrenia; Pharmaceuticals for treating schizotypal and delusional disorders; pharmaceuticals for treating neurotic disorders; Pharmaceuticals for treating stress-related disorders and somatoform disorders; pharmaceuticals for treating behavioural syndromes associated with physiological disturbances and physical factors; pharmaceuticals for treating personality and behavioural disorders due to brain disease; Pharmaceuticals for treating damage and dysfunction; pharmaceuticals for treating disorders of adult personality; pharmaceuticals for treating disorders of behaviour; Pharmaceuticals for treating disorders of psychological development; Pharmaceuticals for treating behavioural and emotional disorders with onset usually occurring in childhood and adolescence; Pharmaceuticals for treating Bipolar disorder; Pharmaceuticals for treating Body dysmorphic disorder; Pharmaceuticals for treating borderline personality disorder; Pharmaceuticals for treating Bulimia; Pharmaceuticals for treating Claustrophobia; Pharmaceuticals for treating Dissociative disorders; Pharmaceuticals for treating Eating disorders; Pharmaceuticals for treating Hoarding disorder; Pharmaceuticals for treating Munchausen's syndrome; Pharmaceuticals for treating Obsessive compulsive disorder; Pharmaceuticals for treating Panic disorder; Pharmaceuticals for treating Personality disorder; Pharmaceuticals for treating Phobias; Pharmaceuticals for treating Postnatal depression; Pharmaceuticals for treating Postpartum psychosis; Pharmaceuticals for treating Post-traumatic stress disorder; Pharmaceuticals for treating Psychosis; Pharmaceuticals for treating Schizophrenia
42
Development of pharmaceutical preparations and medicines; Research of pharmaceuticals; Research relating to pharmaceuticals; Testing of pharmaceuticals; Conducting clinical trials for pharmaceutical products; Consultancy in the field of pharmaceutical research; Conducting early evaluations in the field of new pharmaceuticals; Inspection of pharmaceuticals; Pharmaceutical drug development services; Pharmaceutical product evaluation; Laboratory research services relating to pharmaceuticals; Providing information about the results of clinical trials for pharmaceutical products
ID: 11018597974